Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.87% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
KBH · May 31, 2026
KB HOME. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000795266-26-000063General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
2.87% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.shares_outstanding
-9.91% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
-27.27% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
0.50% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History5 statesHistory building
Period transition
What moved in the state?
- Previous
- 1.23%
- Current
- 0.87%
- Delta
- -0.36%
- Previous
- -11.64%
- Current
- 2.87%
- Delta
- 14.51%
- Previous
- -12.67%
- Current
- -9.91%
- Delta
- 2.76%
- Previous
- -22.62%
- Current
- -27.27%
- Delta
- -4.66%
- Previous
- 0.56%
- Current
- 0.50%
- Delta
- -0.06%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Operative Builders peers →Has State · KB HOME →Transitioned To · KBH Fundamental State →Transitioned To · KBH CAPEX_INTENSITY_DECREASED →Transitioned To · KBH CASH_GENERATION_INCREASED →Transitioned To · KBH DILUTION_INCREASED →Transitioned To · KBH GROWTH_DECREASED →Transitioned To · KBH SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.